Ayala is evaluating the potential of a the investigational drug, AL101. AL101 is a small-molecule that inhibits gamma secretase, an enzyme which plays a key role in the activation of the Notch signaling pathway.
AL101 has completed preclinical and phase 1 studies.
A phase 2 study (ACCURACY) for AL101 in patients with adenoid cystic carcinoma (ACC) bearing activated Notch mutations has been initiated.
Interested patients and physicians can contact Ayala Medical for more information at email ClinicalTrials.gov_Accuracy@ayalapharma.com or call +1-857-444-0553.